Higher concentrations of the soluble EphA2 fragment were detected in patients with gastric carcinoma (460±379 pg/ml) and pancreatic carcinoma (951±317 pg/ml). This evidence concerns the gene EPHA2 and exocrine pancreatic carcinoma.